Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial)

Ricardo A. Costa; Alexandra J. Lansky; Gary S. Mintz; Roxana Mehran; Yoshihiro Tsuchiya; Manuela Negoita; Yael Gilutz; Eugenia Nikolsky; Martin Fahy; Ramona Pop; Ecaterina Cristea; Stephane Carlier; George Dangas; Gregg W. Stone; Martin B. Leon; Ralf Müller; George Techen; Eberhard Grube

doi:10.1016/j.amjcard.2004.08.074

Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial)

Ricardo A. Costa
, Alexandra J. Lansky
, Gary S. Mintz
, Roxana Mehran
, Yoshihiro Tsuchiya
, Manuela Negoita
, Yael Gilutz
, Eugenia Nikolsky
, Martin Fahy
, Ramona Pop
, Ecaterina Cristea
, Stephane Carlier
, George Dangas
, Gregg W. Stone
, Martin B. Leon
, Ralf Müller
, George Techen
, Eberhard Grube

Research output: Contribution to journal › Article › peer-review

72 Scopus citations

Abstract

The purpose of this study was to report the angiographic findings of the first human evaluation of the everolimus-eluting stent (EES) for the treatment of noncomplex coronary lesions. Forty-two patients with de novo coronary lesions (2.75 to 4.00 mm vessels; lesion length, <18 mm) were prospectively randomized in a 2:1 ratio to receive either the EES (n = 27) or a metallic stent (n = 15). Baseline clinical and angiographic characteristics were similar among both groups. At 6-month follow-up, EES had a lower in-stent late lumen loss (0.10 ± 0.22 vs 0.85 ± 0.32 mm, p <0.0001) and in-segment diameter stenoses (20.7 ± 12.3% vs 37.0 ± 15.8%, p = 0.002). There was no in-stent restenosis with EES; however, 1 focal distal edge restenosis was present. There was 1 in-stent and 1 in-segment (proximal edge) restenosis in the metallic stent group. There was no stent thrombosis or aneurysm formation at follow-up in either group.

Original language	English
Pages (from-to)	113-116
Number of pages	4
Journal	American Journal of Cardiology
Volume	95
Issue number	1
DOIs	https://doi.org/10.1016/j.amjcard.2004.08.074
State	Published - 1 Jan 2005
Externally published	Yes

Access to Document

10.1016/j.amjcard.2004.08.074

Cite this

Costa, R. A., Lansky, A. J., Mintz, G. S., Mehran, R., Tsuchiya, Y., Negoita, M., Gilutz, Y., Nikolsky, E., Fahy, M., Pop, R., Cristea, E., Carlier, S., Dangas, G., Stone, G. W., Leon, M. B., Müller, R., Techen, G., & Grube, E. (2005). Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial). American Journal of Cardiology, 95(1), 113-116. https://doi.org/10.1016/j.amjcard.2004.08.074

@article{0cf696ffe4054080a4d39a73123bec73,

title = "Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial)",

abstract = "The purpose of this study was to report the angiographic findings of the first human evaluation of the everolimus-eluting stent (EES) for the treatment of noncomplex coronary lesions. Forty-two patients with de novo coronary lesions (2.75 to 4.00 mm vessels; lesion length, <18 mm) were prospectively randomized in a 2:1 ratio to receive either the EES (n = 27) or a metallic stent (n = 15). Baseline clinical and angiographic characteristics were similar among both groups. At 6-month follow-up, EES had a lower in-stent late lumen loss (0.10 ± 0.22 vs 0.85 ± 0.32 mm, p <0.0001) and in-segment diameter stenoses (20.7 ± 12.3\% vs 37.0 ± 15.8\%, p = 0.002). There was no in-stent restenosis with EES; however, 1 focal distal edge restenosis was present. There was 1 in-stent and 1 in-segment (proximal edge) restenosis in the metallic stent group. There was no stent thrombosis or aneurysm formation at follow-up in either group.",

author = "Costa, \{Ricardo A.\} and Lansky, \{Alexandra J.\} and Mintz, \{Gary S.\} and Roxana Mehran and Yoshihiro Tsuchiya and Manuela Negoita and Yael Gilutz and Eugenia Nikolsky and Martin Fahy and Ramona Pop and Ecaterina Cristea and Stephane Carlier and George Dangas and Stone, \{Gregg W.\} and Leon, \{Martin B.\} and Ralf M{\"u}ller and George Techen and Eberhard Grube",

year = "2005",

month = jan,

day = "1",

doi = "10.1016/j.amjcard.2004.08.074",

language = "English",

volume = "95",

pages = "113--116",

journal = "American Journal of Cardiology",

issn = "0002-9149",

publisher = "Elsevier Inc.",

number = "1",

}

Costa, RA, Lansky, AJ, Mintz, GS, Mehran, R, Tsuchiya, Y, Negoita, M, Gilutz, Y, Nikolsky, E, Fahy, M, Pop, R, Cristea, E, Carlier, S, Dangas, G , Stone, GW, Leon, MB, Müller, R, Techen, G & Grube, E 2005, 'Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial)', American Journal of Cardiology, vol. 95, no. 1, pp. 113-116. https://doi.org/10.1016/j.amjcard.2004.08.074

TY - JOUR

T1 - Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial)

AU - Costa, Ricardo A.

AU - Lansky, Alexandra J.

AU - Mintz, Gary S.

AU - Mehran, Roxana

AU - Tsuchiya, Yoshihiro

AU - Negoita, Manuela

AU - Gilutz, Yael

AU - Nikolsky, Eugenia

AU - Fahy, Martin

AU - Pop, Ramona

AU - Cristea, Ecaterina

AU - Carlier, Stephane

AU - Dangas, George

AU - Stone, Gregg W.

AU - Leon, Martin B.

AU - Müller, Ralf

AU - Techen, George

AU - Grube, Eberhard

PY - 2005/1/1

Y1 - 2005/1/1

N2 - The purpose of this study was to report the angiographic findings of the first human evaluation of the everolimus-eluting stent (EES) for the treatment of noncomplex coronary lesions. Forty-two patients with de novo coronary lesions (2.75 to 4.00 mm vessels; lesion length, <18 mm) were prospectively randomized in a 2:1 ratio to receive either the EES (n = 27) or a metallic stent (n = 15). Baseline clinical and angiographic characteristics were similar among both groups. At 6-month follow-up, EES had a lower in-stent late lumen loss (0.10 ± 0.22 vs 0.85 ± 0.32 mm, p <0.0001) and in-segment diameter stenoses (20.7 ± 12.3% vs 37.0 ± 15.8%, p = 0.002). There was no in-stent restenosis with EES; however, 1 focal distal edge restenosis was present. There was 1 in-stent and 1 in-segment (proximal edge) restenosis in the metallic stent group. There was no stent thrombosis or aneurysm formation at follow-up in either group.

AB - The purpose of this study was to report the angiographic findings of the first human evaluation of the everolimus-eluting stent (EES) for the treatment of noncomplex coronary lesions. Forty-two patients with de novo coronary lesions (2.75 to 4.00 mm vessels; lesion length, <18 mm) were prospectively randomized in a 2:1 ratio to receive either the EES (n = 27) or a metallic stent (n = 15). Baseline clinical and angiographic characteristics were similar among both groups. At 6-month follow-up, EES had a lower in-stent late lumen loss (0.10 ± 0.22 vs 0.85 ± 0.32 mm, p <0.0001) and in-segment diameter stenoses (20.7 ± 12.3% vs 37.0 ± 15.8%, p = 0.002). There was no in-stent restenosis with EES; however, 1 focal distal edge restenosis was present. There was 1 in-stent and 1 in-segment (proximal edge) restenosis in the metallic stent group. There was no stent thrombosis or aneurysm formation at follow-up in either group.

UR - https://www.scopus.com/pages/publications/19944405062

U2 - 10.1016/j.amjcard.2004.08.074

DO - 10.1016/j.amjcard.2004.08.074

M3 - Article

C2 - 15619406

AN - SCOPUS:19944405062

SN - 0002-9149

VL - 95

SP - 113

EP - 116

JO - American Journal of Cardiology

JF - American Journal of Cardiology

IS - 1

ER -

Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial)

Abstract

Access to Document

Fingerprint

Cite this